InnoCan Pharma Corporation

INNO

CA45783P5085

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 11:40:32 2026-02-06 am EST			5-day change	1st Jan Change
6.320 ^CAD	0.00%		-33.26%	-5.67%

Jan. 27	Innocan Pharma Expects Listing on the NYSE American Stock Exchange with Concurrent Offering	MT
Jan. 02	InnoCan Pharma to List on NYSE American Next Week	MT

Innocan Pharma Engages Pain-Management Expert Ahead of FDA Meeting

Published on 07/02/2024 at 04:21 pm EDT - Modified on 07/02/2024 at 04:30 pm EDT

MT Newswires

Latest news about InnoCan Pharma Corporation

Jan. 27	Innocan Pharma Expects Listing on the NYSE American Stock Exchange with Concurrent Offering	MT
Jan. 02	InnoCan Pharma to List on NYSE American Next Week	MT
Jan. 02	Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering	MT
Dec. 10	InnoCan Announces Public Filing of Amended Registration Statement For Proposed U.S. Offering	MT
Nov. 27	Innocan Pharma Nine-month Operating Loss Stable, Revenue Fall 10%	MT
Nov. 26	InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 24	Innocan Pharma Corporation Announces Promising Translational Evidence from A Pain Relief Study of Repeated Lpt-Cbd Administration in Goats	CI
25-10-15	Innocan Pharma Corporation Announces Its Patent for Lpt-Cbd Is Allowed in Japan	CI
25-09-18	Innocan Pharma Corporation Partners with Freedom Farm to Bring Remedy and Hope with its LPT-CBD Injection	CI
25-08-29	InnoCan Pharma Plans One-for-65 Share Consolidation Ahead of Nasdaq Listing	MT
25-08-29	Innocan Pharma announces details of proposed share consolidation	RE
25-08-27	InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-27	Innocan Pharma announces first half of 2025 financial results	RE
25-08-27	Innocan Pharma announces first half of 2025 financial results	RE
25-08-22	Innocan Pharma Corporation to Showcase a Poster Outlining Key Data on LPT-CBD Pharmacokinetics and Efficacy Along with the Recently Published Narrative Review	CI
25-07-23	Innocan Pharma announces public filing of registration statement for proposed U.S. public offering	RE
25-07-23	Innocan Pharma announces public filing of registration statement for proposed U.S. public offering	RE
25-07-03	Chair of Innocan Pharma Resigns	MT
25-07-03	InnoCan Pharma Corporation Announces Executive Changes, Effective July 1, 2025	CI
25-07-03	InnoCan Pharma Corporation Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs	CI
25-06-20	Innocan Pharma to Present Review on Synthetic Cannabidiol for Chronic Pain at PAINWEEK 2025	MT
25-06-20	Innocan Pharma Corporation Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference	CI
25-06-13	Innocan Pharma Endorses Liposomal Synthetic CBD for Chronic Pain Review	MT
25-05-28	InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-28	InnoCan Swings To Q1 Profit On Higher Revenues	MT

Chart InnoCan Pharma Corporation

Duration

Period

INNO: Dynamic Chart

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Employees

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company